REGENERON PHARMACEUTICALS, INC. (REGN) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
REGENERON PHARMACEUTICALS, INC. (REGN) Stock Analysis
Analysis from 10-Q filed 2026-10-30. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 12.2%. FCF margin 22.6%. D/E 0.1x. Source: 10-Q filed 2026-10-30.
| Metric | Value | Context |
|---|---|---|
| ROIC | 12.2% | Solid returns |
| FCF Margin | 22.6% | Strong cash generation |
| Debt/Equity | 0.1x | Conservative leverage |
ROIC 12.2% — Top 25% of sector peers. FCF margin 22.6% — Top 25%.
Explore REGENERON PHARMACEUTICALS, INC.: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for REGN: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: REGENERON PHARMACEUTICALS, INC. earns 12.2% ROIC, Top 25% in Healthcare
ROIC TTM 12.2%, sector median -7.7%, Top 25%. DuPont: NOPAT margin 24.4% × asset turnover 0.4x. Gross margin 85.8%. Operating margin 28.8%. Source: 10-Q filed 2026-10-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 12.2% | Good | Above sector median of -7.7% |
| Return on Equity (ROE) | 15.2% | Good | Efficient use of shareholder equity |
| Gross Margin | 85.8% | Excellent | Strong pricing power |
| Operating Margin | 28.8% | Excellent | Efficient operations |
Cash Flow: REGENERON PHARMACEUTICALS, INC. generates $3.8B FCF at 22.6% margin, positive NaN/8 quarters
FCF TTM $3.8B. FCF margin 22.6%, Top 25%. OCF/Net income 1.0x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-10-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 22.6% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $3.8B | Good | Positive cash generation |
| OCF/Net Income | 1.0x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: REGENERON PHARMACEUTICALS, INC. at 0.1x leverage, 104.2x interest coverage
Debt/Equity 0.1x. Net cash $7.3B. Interest coverage 104.2x. Source: 10-Q filed 2026-10-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.1x | Excellent | Conservative capital structure |
| Net Cash Position | $7.3B | Excellent | Net cash positive |
| Interest Coverage | 104.2x | Excellent | Comfortable debt service |
Valuation: REGENERON PHARMACEUTICALS, INC. trades at 20.4x earnings
P/E 20.4x. EV/Sales 5.4x. FCF yield 3.9%. Dividend yield 0.4%. Source: 10-Q filed 2026-10-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| P/E Ratio | 20.4x | Adequate | Premium valuation |
| EV/Sales | 5.4x | Adequate | Growth premium priced in |
| FCF Yield | 3.9% | Adequate | Lower cash yield |
| Dividend Yield | 0.4% | Adequate | Growth focus over income |
Capital Allocation: REGENERON PHARMACEUTICALS, INC. returns 3.5% shareholder yield, reducing shares 1.6% YoY
Total shareholder yield 3.5% (div 0.4% + buyback 3.1%). Share count -1.6% YoY. Capital returned $3.4B TTM. Source: 10-Q filed 2026-10-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.5% | Good | Dividend + buyback yield combined |
| Buyback Yield | 3.1% | Good | Active share repurchases |
| Share Count Change (YoY) | -1.6% | Good | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $3.4B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 12.2% | Top 25% | - |
| Free Cash Flow Margin | 22.6% | Top 25% | 7.5x above |
| Gross Margin | 85.8% | Top 25% | 1.3x above |
| Operating Margin | 28.8% | Top 25% | - |
| Return on Equity (ROE) | 15.2% | Top 50% | - |
| P/E Ratio | 20.4x | N/A | - |
Financial Scorecard
| Metric | REGN | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 12.2% | Good | Top 25% of sector (median: -7.7%) |
| Free Cash Flow Margin | 22.6% | Excellent | Top 25% of sector (median: 3.0%) |
| Gross Margin | 85.8% | Excellent | Top 25% of sector (median: 63.8%) |
| Debt to Equity Ratio | 5.9% | Excellent | Conservative capital structure |
| P/E Ratio (Price-to-Earnings) | 20.4x | Adequate | Fair value |
| Free Cash Flow Yield | 3.9% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is REGENERON PHARMACEUTICALS, INC.'s Return on Invested Capital (ROIC)?
REGENERON PHARMACEUTICALS, INC. (REGN) has a trailing twelve-month Return on Invested Capital (ROIC) of 12.2%. The 8-quarter median ROIC is 11.3% with a improving trend. Sector median -7.7%. Source: 10-Q filed 2026-10-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s Free Cash Flow Margin?
REGENERON PHARMACEUTICALS, INC. (REGN) has a free cash flow margin of 22.6%, generating $3.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-10-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s P/E ratio and how does it compare to peers?
REGENERON PHARMACEUTICALS, INC. (REGN) trades at a P/E ratio of 20.4x, which is above the sector median of N/A. EV/Sales 5.4x. FCF yield 3.9%. Source: 10-Q filed 2026-10-30.
Q: Does REGENERON PHARMACEUTICALS, INC. pay a dividend?
REGENERON PHARMACEUTICALS, INC. (REGN) currently pays a dividend yield of 0.4%. Total shareholder yield (dividend + buybacks) 3.5%. Source: 10-Q filed 2026-10-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s revenue and earnings growth?
REGENERON PHARMACEUTICALS, INC. (REGN) grew revenue by 18.6% year-over-year. EPS +8.6% YoY. Source: 10-Q filed 2026-10-30.
Q: Is REGENERON PHARMACEUTICALS, INC. buying back stock?
REGENERON PHARMACEUTICALS, INC. (REGN) repurchased $3.0 billion of stock over the trailing twelve months. This represents a buyback yield of 3.1%. Share count -1.6% YoY. Source: 10-Q filed 2026-10-30.
Q: How does REGENERON PHARMACEUTICALS, INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, REGENERON PHARMACEUTICALS, INC. (REGN) shows: ROIC 12.2%, sector median -7.7% (Top 25%). FCF margin 22.6%, sector median 3.0% (Top 25%). Gross margin 85.8%, 22.0pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with REGENERON PHARMACEUTICALS, INC.?
No quantitative warning flags fired for REGENERON PHARMACEUTICALS, INC. (REGN) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-10-30.
Data Source: Data sourced from 10-Q filed 2026-10-30. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms